Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06763731

Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
National Taiwan University Hospital · Academic / Other
Sex
All
Age
20 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Regular use of Systane COMPLETE in dry eye subjects before cataract surgery may optimize the ocular surface.

Detailed description

STUDY OBJECTIVE:To evaluate the impact of predicted residual astigmatism in mixed dry eye patients regularly using Systane COMPLETE before cataract surgery. Hypothesis:Regular use of Systane COMPLETE in mixed dry eye subjects before cataract surgery may lead to more accurate astigmatism predictions. Objectives:To evaluate the Impact of predicted residual astigmatism in mixed dry eye patients regularly using Systane COMPLETE before cataract surgery. Inclusion Criteria The subjects aged 20-85 years, with normal cognitive function and capable of answering related questionnaires who require phacoemulsification and intraocular lens implantation under topical anaesthesia, are the eligible candidates. Exclusion Criteria Unable to answer the questions in the dry eye survey. Ocular trauma or ocular surgery in the planned surgical eye, active ocular infection, and obvious abnormalities in ocular surface or eyelid margins other than MGD cause decreased visual acuity other than cataracts. Dry eye signs: Corneal Fluorescein Staining CFS (+) to exclude any corneal abnormalities or epithelial defect. Systemic drug use, including tetracycline derivatives, antihistamines, and isotretinoin. Using dry eye medication at screening stage. Research Process V1 Screening (1-2 month before surgery) The subjects' demographic information will be collected. The pre-op assessments will be performed, and Informed Consent will be explained and endorsed during this visit. Systane COMPLETE MD1 bottle will be prescribed to all subjects who signed the ICF, with a dosing frequency of 1-2 drops q.i.d OU for 1-2 month. The LENSTAR 900 device (Haag-Streit Swiss) will be used to measure the biometry of the anterior cornea's keratometry at each visit. The measurement will be taken through five consecutive scans with only a few seconds of interval between each scan. The mean keratometry of these five scans will be used. Anterior corneal surface maps from Pentacam (OCULUS, Germany) will be used to identify patients with keratoconus or corneal irregularities at each visits. V2 Pre-operative (7 days before surgery) All participants will receive refractive examinations and take dry eye assessments. Repeat the same biometry measurement as the first visit. The final choice of the IOL for surgery is based on biometry measurements and Barrett Toric calculation. One eye per subject will be analysed. V3 Surgery day The participants will receive phacoemulsification and intraocular lens implantation. The participants with any intra-operative complication will be excluded from the study. To ensure compliance with the medication, it is required that the subjects return the used Systane COMPLETE bottle and medication diary at V3.

Conditions

Interventions

TypeNameDescription
DRUGSystane COMPLETEPreop dry eye management using Systane COMPLETE can help to optimize the ocular surface.

Timeline

Start date
2024-05-02
Primary completion
2026-01-15
Completion
2026-12-31
First posted
2025-01-08
Last updated
2025-11-18

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT06763731. Inclusion in this directory is not an endorsement.